Clinical Trial Highlights

• Improved Treatment of Type 2 Diabetes: Results from the 4B Trial
• Once-Weekly Exenatide Allows Sustained HbA1C Control
• Liraglutide is a Safe and Beneficial Adjunct to Insulin in Glycemic Control in Type 1 Diabetes
• Albiglutide Superior to Sitagliptin and Glimepiride in T2DM
• Once-Weekly Dulaglutide Produces Superior Glycemic Control Compared with Metformin
• Type 1 Diabetes Impairs Education and Employment
• Long-Term Ranibizumab Effective in Diabetic Macular Edema
• Left Ventricular Remodeling Reduced with Olmesartan in ROADMAP
• LEADER Study: Testing the Cardiovascular Safety of Liraglutide
• Cardiovascular Safety of Linagliptin Demonstrated in Pooled Analysis
• ENDURE: Alogliptin Effective and Safe through 2 Years
• Trough DPP-4 Inhibition Differs between the Approved DPP-4 Inhibitors
• Fixed-Ratio Combination of Insulin Degludec and Liraglutide Improves Glycemic Control in Type 2 Diabetes
• Glycemic Improvement with Canagliflozin is Durable in T2DM Patients on Metformin
• New Insulin Glargine Formulation Associated with Less Nocturnal Hypoglycemia
• Initial Triple Therapy Superior to Stepwise Add-On Therapy in Newly Diagnosed Type 2 Diabetes